DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02077946

Completed

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

1,059

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02077946
Org study IDNN2211-4161
Secondary IDU1111-1151-9632WHO

Timeline

Milestones

Study start2014-02-10actual
Study first posted2014-03-04estimated
Primary completion2014-09-03actual
Study completion2014-09-03actual
Last update posted2017-05-31actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Data will be analyzed for patients with type 2 diabetes treated with liraglutide or sitagliptin from January 2010 to December 2013, with a treatment length of 180 days.

Inclusion criteria

•Patients from EMR (electronic medical record) system in the primary care in Sweden
•Patients equal to or more than 18 years of age
•Starting treatment with liraglutide or sitagliptin from January 2010 to December 2013
•Minimum of 180 days of prior follow-up/history within the database before their index date

Exclusion criteria

•Patients with cancer, end stage liver disease, end stage renal failure (non-diabetes related)
•Female patients with gestational diabetes during pregnancy
•Patients with previous GLP-1 (glucagon-like peptide-1) or DPP-IV (dipeptidyl peptidase-4 ) inhibitor use, i.e. patients should be incretin naïve

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Cardiometabolic biomarkers
2
Weight & body composition
1
Renal / kidney
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change in weight (in kilograms)

Time frame:Day 0, Day 180

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction

Time frame:Day 0, Day 180

HbA1c, change

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percent (%) of patients with HbA1c (glycosylated haemoglobin) reduction at least 1 %-point and weight reduction at least 3% (NICE clinical guidelines, liraglutide only)

Time frame:Day 0, Day 180

threshold achievement, improvement

componentsHbA1c, change, Body weight, % change

Secondary/protocol endpoint

HbA1c (NGSP standard, in %) change

Time frame:Day 0, Day 180

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Renal / kidney

1 endpoint
Secondary/protocol endpoint

Change in creatinine

Time frame:Day 0, Day 180

change from baseline, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Change in blood pressure (systolic, in mmHg)

Time frame:From baseline to 180 days of therapy

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in lipids (HDL, LDL and triglycerides, in mmol/L)

Time frame:Day 0, Day 180

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.